NCT01156259

30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy

Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 15 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether 30Gy Involved-field Radiotherapy (IFRT) is as effective as 40Gy in the treatment of localized Diffused Large B cell Lymphoma (DLBCL) when completing CR after chemotherapy.

Detailed description

The best proper doses of IFRT in combined modality treatments (CMT) for localized DLBCL is still undetermined. Existing treatment guidelines recommend 40Gy or above as the standard treatment dosage. However, there were large-scaled clinical trials implying smaller doses such as 30Gy may be equivalent effective. Lowering radiation doses can decrease treatment toxicities and radiotherapy-induced diseases, which has been conformed by HD13 study for Hodgkin's Lymphoma. It may even retain the truth when modern era radiation techniques are involved and especially in patients achieving CR after chemotherapy. A comprehensive, prospective dose-comparing study is needed.

Conditions

• Lymphoma, Large B-Cell, Diffuse

Interventions

Type	Name	Description
RADIATION	3D-CRT based Involved Field Radiotherapy	CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
RADIATION	3D-CRT based Involved Field Radiotherapy	CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy

Timeline

• Start date: 2010-04-01
• Primary completion: 2015-04-01
• Completion: 2015-05-01
• First posted: 2010-07-02
• Last updated: 2010-07-02

Locations

1 site across 1 country: China